Organogenesis (ORGO) Competitors $3.18 +0.13 (+4.26%) (As of 12/23/2024 05:35 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ORGO vs. EVO, KNSA, RCUS, PRAX, IMCR, NRIX, TVTX, OCUL, SEPN, and DAWNShould you be buying Organogenesis stock or one of its competitors? The main competitors of Organogenesis include Evotec (EVO), Kiniksa Pharmaceuticals (KNSA), Arcus Biosciences (RCUS), Praxis Precision Medicines (PRAX), Immunocore (IMCR), Nurix Therapeutics (NRIX), Travere Therapeutics (TVTX), Ocular Therapeutix (OCUL), Septerna (SEPN), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Organogenesis vs. Evotec Kiniksa Pharmaceuticals Arcus Biosciences Praxis Precision Medicines Immunocore Nurix Therapeutics Travere Therapeutics Ocular Therapeutix Septerna Day One Biopharmaceuticals Organogenesis (NASDAQ:ORGO) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation. Does the MarketBeat Community prefer ORGO or EVO? Organogenesis received 91 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 66.44% of users gave Organogenesis an outperform vote while only 54.55% of users gave Evotec an outperform vote. CompanyUnderperformOutperformOrganogenesisOutperform Votes9766.44% Underperform Votes4933.56% EvotecOutperform Votes654.55% Underperform Votes545.45% Do analysts prefer ORGO or EVO? Organogenesis currently has a consensus price target of $5.33, indicating a potential upside of 67.71%. Evotec has a consensus price target of $5.93, indicating a potential upside of 33.03%. Given Organogenesis' stronger consensus rating and higher possible upside, equities analysts plainly believe Organogenesis is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Evotec 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has more volatility and risk, ORGO or EVO? Organogenesis has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Evotec has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Which has preferable valuation & earnings, ORGO or EVO? Organogenesis has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$455.04M0.88$4.95M-$0.06-53.00Evotec$777.05M2.03-$90.82MN/AN/A Is ORGO or EVO more profitable? Evotec has a net margin of 0.00% compared to Organogenesis' net margin of -1.62%. Evotec's return on equity of 0.00% beat Organogenesis' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-1.62% -2.69% -1.63% Evotec N/A N/A N/A Does the media favor ORGO or EVO? In the previous week, Evotec had 1 more articles in the media than Organogenesis. MarketBeat recorded 2 mentions for Evotec and 1 mentions for Organogenesis. Evotec's average media sentiment score of 1.57 beat Organogenesis' score of 1.22 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals believe in ORGO or EVO? 49.6% of Organogenesis shares are held by institutional investors. Comparatively, 5.8% of Evotec shares are held by institutional investors. 36.9% of Organogenesis shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryOrganogenesis beats Evotec on 9 of the 16 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Organogenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGO vs. The Competition Export to ExcelMetricOrganogenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$421.60M$6.69B$5.20B$9.14BDividend YieldN/A3.00%5.12%4.28%P/E Ratio-53.0010.5686.9017.12Price / Sales0.93193.811,138.53122.82Price / Cash15.8157.1643.2337.84Price / Book1.515.134.804.78Net Income$4.95M$151.58M$120.46M$225.43M7 Day Performance-10.92%-1.40%-0.94%-0.82%1 Month Performance-21.48%-3.68%14.81%1.02%1 Year Performance-19.70%9.07%29.53%15.72% Organogenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGOOrganogenesis4.3079 of 5 stars$3.18+4.3%$5.33+67.7%-19.7%$383.46M$455.04M-53.00950Positive NewsEVOEvotec2.5971 of 5 stars$4.44-0.7%$5.93+33.6%-61.5%$1.57B$777.05M0.005,061Positive NewsKNSAKiniksa Pharmaceuticals2.53 of 5 stars$20.46-0.6%$36.60+78.9%+11.0%$1.48B$384.10M-146.13220Positive NewsRCUSArcus Biosciences2.8586 of 5 stars$15.50flat$34.00+119.4%-12.1%$1.42B$263M-4.92500PRAXPraxis Precision Medicines2.2316 of 5 stars$76.00-0.7%$146.33+92.5%+281.0%$1.42B$1.61M-7.38110IMCRImmunocore2.5288 of 5 stars$28.24-0.3%$65.64+132.4%-57.1%$1.41B$296.31M-29.73497NRIXNurix Therapeutics2.5403 of 5 stars$19.92+0.5%$30.35+52.4%+108.8%$1.41B$56.42M-6.85300TVTXTravere Therapeutics2.6052 of 5 stars$17.08-0.6%$23.67+38.6%+89.3%$1.33B$203.45M-3.75460Positive NewsOCULOcular Therapeutix3.6921 of 5 stars$8.44-0.7%$16.71+98.0%+106.8%$1.33B$61.44M-6.39267SEPNSepterna2.0353 of 5 stars$28.98+19.4%$43.67+50.7%N/A$1.29B$981,000.000.00N/ANews CoverageDAWNDay One Biopharmaceuticals1.506 of 5 stars$12.60-1.5%$35.71+183.4%-15.6%$1.27B$101.95M-12.2360Positive News Related Companies and Tools Related Companies Evotec Alternatives Kiniksa Pharmaceuticals Alternatives Arcus Biosciences Alternatives Praxis Precision Medicines Alternatives Immunocore Alternatives Nurix Therapeutics Alternatives Travere Therapeutics Alternatives Ocular Therapeutix Alternatives Septerna Alternatives Day One Biopharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ORGO) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organogenesis Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organogenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGO Stock Alerts